Guanfacine Hydrochloride
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Guanfacine Hydrochloride |
| DrugBank ID | DB01018 |
| Brand Names (EU) | Paxneury |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.99% |
Approved Indication (EMA)
Paxneury is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6‑17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. Paxneury must be used as a part of a comprehensive ADHD treatment programme, typically including psychological, educational and social measures.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | attention deficit hyperactivity disorder, inattentive type | 99.99% | DL |
| 2 | attention deficit-hyperactivity disorder | 99.98% | DL |
| 3 | faciodigitogenital syndrome | 99.97% | DL |
| 4 | specific developmental disorder | 99.97% | DL |
| 5 | chondromyxoid fibroma | 99.94% | DL |
| 6 | trichotillomania | 99.79% | DL |
| 7 | manic bipolar affective disorder | 99.72% | DL |
| 8 | restless legs syndrome | 99.64% | DL |
| 9 | Tourette syndrome | 99.27% | DL |
| 10 | postural orthostatic tachycardia syndrome | 99.10% | DL |
| 11 | multiple system atrophy | 98.19% | DL |
| 12 | variably protease-sensitive prionopathy | 97.66% | DL |
| 13 | migraine disorder | 97.22% | DL |
| 14 | migraine with brainstem aura | 96.92% | DL |
| 15 | hypotrichosis simplex of the scalp | 96.79% | DL |
| 16 | congenital hypotrichosis milia | 96.48% | DL |
| 17 | major affective disorder | 96.06% | DL |
| 18 | diffuse alopecia areata | 95.48% | DL |
| 19 | primary hereditary glaucoma | 95.20% | DL |
| 20 | cerebellar ataxia | 94.69% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.